应用希罗达所致手足综合征的临床观察及护理(1)
 |
| 第1页 |
参见附件(2264KB，2页)。
[摘要] 目的：观察塞来昔布联合维生素B6防治希罗达所致手足综合征的临床效果及护理措施。方法：将符合条件的恶性肿瘤患者82例随机分为观察组(42例)和对照组(40例)。两组化疗方案相同。观察组予以口服塞来昔布和维生素B6，同时给予对症及心理护理，对照组无预防性药物及给予常规护理。结果：观察组手足综合征发生率为11.9%，对照组手足综合征发生率为52.5%，两组比较，差异有高度统计学意义(χ2=15.592，P<0.01)。结论：塞来昔布联合维生素B6可有效防治希罗达所致手足综合征的发生，及时的护理可明显缓解症状，缓解患者的紧张情绪，保护好皮肤，防止症状进一步发展。
[关键词] 塞来昔布；维生素B6；希罗达；手足综合征；护理
[中图分类号] R73 [文献标识码] A [文章编号] 1673-7210(2011)06(c)-134-02
Observation and nursing on applications Xeloda cause Hand-foot syndrome
LI Youqiong1, YANG Qingru1, LIANG Bingrong2
1.The People′s Hospital of Boluo County, Guangdong Province, Boluo 516100, China; 2. The Jiutan People′s Hospital of Boluo County, Guangdong Province, Boluo 516133, China
[Abstract] Objective: To investigate the effecting and nursing methods on Celecoxib combine with Vitamin B6 in the treatment of Hand-foot syndrome (HFS) which was induced from Xeloda. Methods: 82 patients with m alignant tumor were selected. All patients were randomly divided into observation group and control group, and two groups were administrated with the same chemotherapy regimen. Patients in observation group were administrated with oral Celecoxib combine with Vitamin B6, and symptomatic and psychological nursing were given to them, while patitents in control group with no preventive drugs and conventional nursing. Results: The incidence of observation group was 11.9% and control group was 52.5%, there was a significant difference in two groups (χ2=15.592, P<0.01). Conclusion: Celecoxib combine with Vitamin B6 are effective in treatment of Hand-foot syndrome which was induced from Xelada, the nursing work could relieve the symptom and the nervous mood, protect the patients′ skin, and avoid the further development.
[Key words] Celecoxib; Vitamin B6; Xelada; Hand-foot syndrome; Nursing
希罗达(卡培他滨，Xelada)是一种新型的口服氟嘧啶核苷类药物，主要用于治疗晚期结肠癌、直肠癌、乳腺癌和胃癌，疗效肯定且骨髓毒性较轻，患者耐受性好，但是该药副反应手足综合症的发生率较高，影响了化疗患者的生活质量。本文中笔者对塞来昔布联合维生素B6防治希罗达所致手足综合征的临床疗效及护理措施进行了观察，发现早期预防治疗及护理干预可将患者的不适减到最小，有利于治疗。现报道如下：
1 资料与方法
1.1 一般资料
选取2008年10月~2010年10月我院符合条件的恶性肿瘤患者82例，将其随机分为观察组(42例)和对照组(40例)。所有患者入选条件：经病理检查证实的结肠癌、直肠癌、乳腺癌，临床分期3~4期，karnofsky评分70~100分，预计生存期>3个月。排除条件：年龄<18岁或>80岁，严重心、肝、肾功能衰竭，患有精神疾病，不配合治疗者 ......
您现在查看是摘要介绍页，详见PDF附件(2264KB，2页)。